CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
OCV-103 and OCV-104 +3 moredrug
Likely dose
OCV-103 and OCV-104 0.3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01801930
NCT01801930Phase 1Completed
CompareCT.gov

A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy

Otsuka Pharmaceutical Co., Ltd.·interventional·Posted Mar 1, 2013·Updated Feb 26, 2021

In Brief

A Phase 1 clinical trial evaluating OCV-103 and OCV-104 for Colorectal Cancer. Completed, enrolled 24 participants across 3 sites.

Detailed Summary

To assess the safety and tolerability of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 1, 2013
Enrollment StartMar 1, 2013
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.3 years ago

Interventions

OCV-103 and OCV-104drug

0.3 mg of each

OCV-103 and OCV-104drug

1 mg of each

OCV-103 and OCV-104drug

3 mg of each

OCV-103 and OCV-104drug

6 mg of each